00000000cam 2200000zi 4500
0019.962824
003CaOODSP
00520260525120847
006m     o  d f      
007cr cn ||||||||
008260515t20262026onc     o    f000 0 eng d
020 |a9780660999661
040 |aCaOODSP|beng|erda|cCaOODSP
043 |an-cn---
0861 |aH164-427/2026E-PDF
24500|aGuidance on information and submission requirements for biosimilar biologic drugs.
264 1|aOttawa : |bHealth Canada = Santé Canada, |c2026.
264 4|c©2026
300 |a1 online resource (i, 30 pages)
336 |atext|btxt|2rdacontent
337 |acomputer|bc|2rdamedia
338 |aonline resource|bcr|2rdacarrier
500 |aIssued also in French under title: Lignes directrices sur les exigences en matière de renseignements et de présentation relatives aux médicaments biologiques biosimilaires.
520 |a"This guidance document applies to all biologic drug submissions for which the sponsor seeks authorization for sale based on a demonstrated high degree of similarity to a previously authorized biologic drug. These submissions rely on prior information regarding that biologic drug to support, in part, a reduced clinical package as part of the submission"--page 3.
650 0|aBiologicals|xGovernment policy|zCanada.
650 0|aDrug approval|zCanada.
7101 |aCanada. |bHealth Canada, |eissuing body.
77508|tLignes directrices sur les exigences en matière de renseignements et de présentation relatives aux médicaments biologiques biosimilaires.|w(CaOODSP)9.962825
85640|qPDF|s742 KB|uhttps://publications.gc.ca/collections/collection_2026/sc-hc/H164-427-2026-eng.pdf
8564 |qHTML|sN/A|uhttps://www.canada.ca/en/health-canada/services/drugs-health-products/biologics-radiopharmaceuticals-genetic-therapies/applications-submissions/guidance-documents/information-submission-requirements-biosimilar-biologic-drugs.html
986 |a260112